April 01, 2026

FDA Broadens CFTR Therapy Eligibility

The FDA expanded use of CFTR modulators to include more CF gene variants, increasing treatment eligibility across a wider US patient population.

Conexiant

April 01, 2026

Bipolar Psychosis: Examining Diagnostic Boundaries

Investigators synthesize schizophrenia comorbidity and psychotic symptom profiles across bipolar populations.

Conexiant

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 30, 2026

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

Conexiant

March 27, 2026

FDA Approves Gene Therapy for Severe Pediatric LAD-I

Approval expands treatment option for a rare pediatric immunodeficiency

Conexiant

March 27, 2026

Meningococcal Abscess Detected by MRI

MRI identifies rare intracranial complication following normal computed tomography

Conexiant

March 26, 2026

Turning Baby Teeth Into Cell Therapy

SHED cells show early promise as a potential regenerative therapy in cerebral palsy research

The Medicine Maker

March 18, 2026

AAP, NASPGHAN Issue Guidance on Faltering Weight in Children

New recommendations standardize diagnosis and aim to reduce unnecessary interventions in early childhood growth concerns.

Conexiant

March 13, 2026

Clinicians Warn of Fatal Measles Brain Disease

Doctors caution that measles infection can lead to SSPE, a rare fatal neurologic disease that may appear years later.

KFF Health News

March 12, 2026

Childhood Oral Health Linked to Adult Cardiovascular Risk

Study links childhood dental disease with higher incidence of ischemic heart disease, myocardial infarction, and ischemic stroke in adulthood.

Conexiant